• Hadziyannis S. Sette J. Morgan T. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C, a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004, 140, 346-355.
  • Manns M. McHutchison J. Gordon S. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C, a randomised trial. Lancet, 2001, 358, 958-965.
  • Ивашкин В.Т. Лобзин Ю.В. Сторожаков Г.И. и др. Эффективность и безопасность 48-недельной комбинированной терапии пэгинтерфероном a-2a и рибавирином у первичных больных хроническим гепатитом С. Многоцентровое российское исследование. Клин. фармакол. тер. 2007, 16 (1), 22-26.
  • Formann E. Steindl-Munda P. Hofer H. et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment. Pharmacol. Ther. 2006, 23 (4), 507-511.
  • Maylin S. Martinot-Peignoux M. Moucari R. et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology, 2008, 135 (3), 821-829.
  • Swain М. Lai M.-Y. Shiffman М. et al. Sustained virologic response (SVR) resulting from treatment with peginterferon alfa-2a (40KD) alone or in combination with ribavirin is durable and constitutes a cure: an ongoing 5-year follow-up. Gastroenterology, 2007, 132 (Suppl. 1), 741A.
  • Everson G. Balart L. Lee S. et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis and advanced fibrosis or compensated cirrhosis. Aliment. Pharmacol. Ther. 2008, 27 (7), 542-551.
  • Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology, 2002, 122, 1303-1313.
  • Bizollon T. Ahmed S. Radenne S. et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut, 2003, 52 (2), 283-287.
  • Kornberg A. K_pper B. Tannapfel A. et al. Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C. Transplantation, 2008, 86 (3), 469-473.
  • Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 2000, 132, 517-524.
  • Soriano V, Maida I, N__ez M, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferonbased therapies. Antivir. Ther. 2004, 9 (6), 987-992.
  • Huang J. Yu M. Lee C. et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. Aliment. Pharmacol. Ther. 2007, 25 (9), 1029-1037.
  • Veldt B. Saracco G. Boyer N. et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut, 2004, 53 (10), 1504-1508.
  • Tanaka H. Tsukuma H. Kasahara A. et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int. Cancer, 2000, 87 (5), 741-749.
  • Camma C. Giunta M. Andreone P. Crax_ A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. Hepatol. 2001, 34 (4), 593-602.
  • Hung C. Lee C. Lu S. et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J. Viral Hepat. 2006, 13 (6), 409-414.
  • Клиническая гепатология, 2009, 2

    Источник:http://gepatit-c.ru/articles/qhgc.html